| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Kirby John J. | Interim CFO | C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER | /s/ John J. Kirby | 25 Nov 2025 | 0001556327 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRCA | Common Stock | Purchase | $15,001 | +3,536 | +65% | $4.24 | 8,962 | 25 Nov 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRCA | Series C Warrant (right to buy) | Purchase | +884 | 884 | 25 Nov 2025 | Common Stock | 884 | $6.32 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. |
| F2 | Immediately exercisable. |
| F3 | The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |